JP2016501221A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016501221A5 JP2016501221A5 JP2015545145A JP2015545145A JP2016501221A5 JP 2016501221 A5 JP2016501221 A5 JP 2016501221A5 JP 2015545145 A JP2015545145 A JP 2015545145A JP 2015545145 A JP2015545145 A JP 2015545145A JP 2016501221 A5 JP2016501221 A5 JP 2016501221A5
- Authority
- JP
- Japan
- Prior art keywords
- inhibitor
- pharmaceutical composition
- composition according
- cdk4
- represented
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 10
- 239000003795 chemical substances by application Substances 0.000 claims 6
- 229940124297 CDK 4/6 inhibitor Drugs 0.000 claims 4
- 102000013701 Cyclin-Dependent Kinase 4 Human genes 0.000 claims 4
- 108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 claims 4
- 229940124302 mTOR inhibitor Drugs 0.000 claims 4
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 claims 4
- 229940126062 Compound A Drugs 0.000 claims 2
- 102000013698 Cyclin-Dependent Kinase 6 Human genes 0.000 claims 2
- 108010025468 Cyclin-Dependent Kinase 6 Proteins 0.000 claims 2
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 claims 2
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 claims 2
- 239000002875 cyclin dependent kinase inhibitor Substances 0.000 claims 2
- 229940043378 cyclin-dependent kinase inhibitor Drugs 0.000 claims 2
- 229960005167 everolimus Drugs 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 208000008938 Rhabdoid tumor Diseases 0.000 claims 1
- 201000007281 estrogen-receptor positive breast cancer Diseases 0.000 claims 1
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261730661P | 2012-11-28 | 2012-11-28 | |
US61/730,661 | 2012-11-28 | ||
PCT/US2013/071659 WO2014085318A1 (en) | 2012-11-28 | 2013-11-25 | Combination therapy |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018176231A Division JP2019031500A (ja) | 2012-11-28 | 2018-09-20 | 併用療法 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2016501221A JP2016501221A (ja) | 2016-01-18 |
JP2016501221A5 true JP2016501221A5 (US07794700-20100914-C00125.png) | 2017-01-12 |
Family
ID=49753505
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015545145A Withdrawn JP2016501221A (ja) | 2012-11-28 | 2013-11-25 | 併用療法 |
JP2018176231A Withdrawn JP2019031500A (ja) | 2012-11-28 | 2018-09-20 | 併用療法 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018176231A Withdrawn JP2019031500A (ja) | 2012-11-28 | 2018-09-20 | 併用療法 |
Country Status (12)
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20140040770A (ko) * | 2011-07-01 | 2014-04-03 | 노파르티스 아게 | 암 치료에 사용하기 위한 cdk4/6 억제제 및 pi3k 억제제를 포함하는 조합 요법 |
EP2968291A4 (en) | 2013-03-15 | 2016-09-28 | G1 Therapeutics Inc | HSPC-PROOF TREATMENTS FOR RB-POSITIVE ABNORMAL CELLULAR PROLIFERATION |
EP3049442A4 (en) | 2013-09-26 | 2017-06-28 | Costim Pharmaceuticals Inc. | Methods for treating hematologic cancers |
JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
JOP20200096A1 (ar) | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | جزيئات جسم مضاد لـ tim-3 واستخداماتها |
CN106103484B (zh) | 2014-03-14 | 2021-08-20 | 诺华股份有限公司 | 针对lag-3的抗体分子及其用途 |
US9421264B2 (en) | 2014-03-28 | 2016-08-23 | Duke University | Method of treating cancer using selective estrogen receptor modulators |
LT3122426T (lt) | 2014-03-28 | 2023-03-10 | Duke University | Krūties vėžio gydymas, naudojant selektyvius estrogenų receptorių moduliatorius |
CN107206071A (zh) | 2014-09-13 | 2017-09-26 | 诺华股份有限公司 | Alk抑制剂的联合疗法 |
US20170209574A1 (en) | 2014-10-03 | 2017-07-27 | Novartis Ag | Combination therapies |
MA41044A (fr) | 2014-10-08 | 2017-08-15 | Novartis Ag | Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer |
UY36351A (es) | 2014-10-14 | 2016-06-01 | Novartis Ag | Moléculas de anticuerpo que se unen a pd-l1 y usos de las mismas |
PE20171448A1 (es) | 2015-03-10 | 2017-10-02 | Aduro Biotech Inc | Composiciones y metodos para activar la senalizacion dependiente del estimulador del gen de interferon |
CN106336412A (zh) * | 2015-07-10 | 2017-01-18 | 南开大学 | 作为cdk4/6抑制剂的2-(n-氧化芳环-2基氨基)-吡咯并嘧啶及嘌呤类化合物 |
EP3964528A1 (en) | 2015-07-29 | 2022-03-09 | Novartis AG | Combination therapies comprising antibody molecules to lag-3 |
EP4378957A2 (en) | 2015-07-29 | 2024-06-05 | Novartis AG | Combination therapies comprising antibody molecules to pd-1 |
US20180207273A1 (en) | 2015-07-29 | 2018-07-26 | Novartis Ag | Combination therapies comprising antibody molecules to tim-3 |
EP3156406A1 (en) * | 2015-10-14 | 2017-04-19 | ratiopharm GmbH | Crystalline forms of ribociclib free base |
PL3370768T3 (pl) | 2015-11-03 | 2022-06-13 | Janssen Biotech, Inc. | Przeciwciała specyficznie wiążące pd-1 i ich zastosowania |
JP2019503349A (ja) | 2015-12-17 | 2019-02-07 | ノバルティス アーゲー | Pd−1に対する抗体分子およびその使用 |
CA3027563A1 (en) * | 2016-06-22 | 2017-12-28 | Radius Health, Inc. | Ar+ breast cancer treatment methods |
EP3507367A4 (en) | 2016-07-05 | 2020-03-25 | Aduro BioTech, Inc. | CYCLIC DINUCLEOTID COMPOUNDS WITH INCLUDED NUCLEIC ACIDS AND USES THEREOF |
WO2018081211A1 (en) * | 2016-10-26 | 2018-05-03 | Li George Y | Deuterated 7-cyclopentyl-n, n-dimethyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-7h-pyrrolo[2,3-d]pyrimdine-6-carboxamide |
AU2018234903B2 (en) * | 2017-03-16 | 2024-02-08 | Eisai R&D Management Co., Ltd. | Combination therapies for the treatment of breast cancer |
UY37695A (es) | 2017-04-28 | 2018-11-30 | Novartis Ag | Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo |
EP3642240A1 (en) | 2017-06-22 | 2020-04-29 | Novartis AG | Antibody molecules to cd73 and uses thereof |
WO2018237157A1 (en) | 2017-06-22 | 2018-12-27 | Novartis Ag | CD73 BINDING ANTIBODY MOLECULES AND USES THEREOF |
US20210214459A1 (en) | 2018-05-31 | 2021-07-15 | Novartis Ag | Antibody molecules to cd73 and uses thereof |
AU2019384292A1 (en) | 2018-11-23 | 2021-01-14 | Ascentage Pharma (Suzhou) Co., Ltd. | Novel pharmaceutical composition and use thereof |
US10988479B1 (en) | 2020-06-15 | 2021-04-27 | G1 Therapeutics, Inc. | Morphic forms of trilaciclib and methods of manufacture thereof |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011130232A1 (en) * | 2010-04-13 | 2011-10-20 | Novartis Ag | Combination comprising a cyclin dependent kinase 4 or cyclin dependent kinase (cdk4/6) inhibitor and an mtor inhibitor for treating cancer |
-
2013
- 2013-11-25 BR BR112015012197A patent/BR112015012197A8/pt not_active IP Right Cessation
- 2013-11-25 WO PCT/US2013/071659 patent/WO2014085318A1/en active Application Filing
- 2013-11-25 US US14/646,206 patent/US9408847B2/en not_active Expired - Fee Related
- 2013-11-25 CN CN201380061379.0A patent/CN104812414A/zh active Pending
- 2013-11-25 MX MX2015006809A patent/MX2015006809A/es unknown
- 2013-11-25 KR KR1020157016810A patent/KR20150089053A/ko not_active Application Discontinuation
- 2013-11-25 CA CA2891938A patent/CA2891938A1/en not_active Abandoned
- 2013-11-25 RU RU2015125307A patent/RU2015125307A/ru not_active Application Discontinuation
- 2013-11-25 EP EP13802807.1A patent/EP2925365A1/en not_active Withdrawn
- 2013-11-25 JP JP2015545145A patent/JP2016501221A/ja not_active Withdrawn
- 2013-11-25 AU AU2013352406A patent/AU2013352406A1/en not_active Abandoned
-
2015
- 2015-12-14 HK HK15112282.5A patent/HK1211475A1/xx unknown
-
2016
- 2016-11-25 AU AU2016262781A patent/AU2016262781A1/en not_active Abandoned
-
2018
- 2018-01-15 AU AU2018200323A patent/AU2018200323A1/en not_active Abandoned
- 2018-09-20 JP JP2018176231A patent/JP2019031500A/ja not_active Withdrawn
-
2019
- 2019-02-08 AU AU2019200881A patent/AU2019200881A1/en not_active Ceased
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2016501221A5 (US07794700-20100914-C00125.png) | ||
RU2015125307A (ru) | Комбинированная терапия | |
CY1123627T1 (el) | Παραγωγα διυδροϊμιδαζοπυραζινονης χρησιμα στη θεραπευτικη αντιμετωπιση του καρκινου | |
CN106687454B8 (zh) | 作为细胞周期蛋白依赖性激酶(cdk)抑制剂的2h-吲唑衍生物及其医疗用途 | |
GEP20237479B (en) | Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer | |
JP2016533366A5 (US07794700-20100914-C00125.png) | ||
JP2015508103A5 (US07794700-20100914-C00125.png) | ||
CY1119227T1 (el) | Παραγωγα πυριδινης ως ηπιοι αναστολεις της rock | |
EA201600204A1 (ru) | Производные хиназолина, фармацевтическая композиция на их основе и их применение для профилактики или лечения опухоли | |
EA202092671A1 (ru) | Оптимизированная комбинированная терапия и ее применение для лечения злокачественной опухоли и аутоиммунного заболевания | |
JP2015536964A5 (US07794700-20100914-C00125.png) | ||
JP2017524735A5 (US07794700-20100914-C00125.png) | ||
JP2011102304A5 (US07794700-20100914-C00125.png) | ||
MX2015011245A (es) | Un inhibidor de mdm2 derivado de acido benzoico para el tratamiento del cancer. | |
JP2013522326A5 (US07794700-20100914-C00125.png) | ||
MX2017011635A (es) | Combinaciones que contienen 2,3-dihidroimidazo[1,2-c]quinazolina sustituida. | |
RU2016110874A (ru) | Комбинация ингибитора alk и ингибитора cdk для лечения клеточных пролиферативных заболеваний | |
MX2015016421A (es) | Derivados de pirazolo-pirrolidin-4-ona como inhibidores de bet y su uso en el tratamiento de enfermedades. | |
MX2015016425A (es) | Derivados de pirazolo-pirrolidin-4-ona y su uso en el tratamiento de enfermedades. | |
IL307260A (en) | A method for treating cancer | |
MX2013012588A (es) | Inhibidores de cinasa. | |
JP2017517565A5 (US07794700-20100914-C00125.png) | ||
JP2015516419A5 (US07794700-20100914-C00125.png) | ||
JP2015502926A5 (US07794700-20100914-C00125.png) | ||
PH12014502547A1 (en) | Dosage regimen for a pi-3 kinase inhibitor |